The U.S. Food and Drug Administration (FDA) has cleared for use Toshiba America Medical Systems’ extra-large knee array coil for the Vantage TitanTM MR system. Toshiba claims to be the first diagnostic imaging vendor to offer an extra-large knee coil with a 22-cm interior diameter for MR imaging.

An improved algorithm can dramatically enhance the capture and interpretation of full-body MRIs, particularly in the abdominal region, according to a new study slated for presentation Thursday at the annual meeting of the American Roentgen Ray Society (ARRS) in Chicago.

While PET/CT is commonly and very successfully used for the staging and follow-up of cancers, researchers are seeking ways to make the modality more sensitive and specific by using targeted radiotracers and refining scanning techniques.

PET imaging can play an invaluable role in monitoring the effects of cancer therapies. In my view, cancer therapies that do not achieve early reductions in FDG uptake cannot be effective.

A new day is dawning for breast cancer diagnosis, treatment and monitoring with the help of molecular imaging.

Radiation was brought to the fore within pediatric nuclear medicine following the release of a 2008 study which revealed a chaotic disarray of administered doses within North Americas premier pediatric institutions, including radiopharmaceutical doses varying by factors of as much as 10 in most children and by up to 20 in infants (J Nucl Med 2008; 49:10241027).

Last year, the SNM received a $48,000 grant from the Agency for Healthcare Research and Quality to develop comparative-effectiveness research (CER) of PET and other molecular imaging techniques. The primary emphasis is on the diagnosis and management of cancer patients, but both cardiology and neurology questions are being addressed. Far beyond the dollars, too, is a significant increase in intellectual capital being expended across the globe on the role of CER in molecular imaging. 

Researchers at Memorial Sloan-Kettering Cancer Center, along with collaborators at Cornell University and Hybrid Silica Technologies, have received approval for their first Investigational New Drug Application (IND) from the U.S. Food and Drug Administration (FDA) for an ultrasmall inorganic (silica) nanoparticle platform for tumor targeting and for the treatment of cancers in the future.